Synergistic combinations and peptides in the inhibition of human immunodeficiency virus
- PMID: 1715118
- DOI: 10.1016/0065-2571(91)90010-j
Synergistic combinations and peptides in the inhibition of human immunodeficiency virus
Abstract
Various combinations of inhibitors of HIV reverse transcriptase were tested for inhibition of HIV replication in order to reveal any potential synergism or antagonism. PFA, a pyrophosphate analogue, gave synergistic inhibition of HIV replication in combination with both of the thymidine analogues AZT and FLT. The combination of PFA and AZT-TP gave only additive or weakly synergistic inhibition in a reverse transcriptase enzyme assay. The combination of AZT and FLT also gave synergistic inhibition of HIV replication, whilst the combination of AZT-TP and FLT-TP gave only additive or weakly synergistic inhibition of reverse transcriptase. Thus, the synergy does not arise from effects on reverse transcriptase alone but must be owing to other, cellular factors, such as effects on nucleoside metabolism or metabolism of the analogues. The results are consistent with the hypothesis that AZT may have an alternative mechanism of inhibition other than inhibition of reverse transcriptase. The diminished cytotoxicity observed in addition to the synergistic inhibition makes these combinations attractive from the point of view of combination chemotherapy. The inhibition of HIV replication by peptides from various parts of the V3 region of gp120 whose sequences were homologous with the tryptase inhibitor trypstatin was tested. Inhibitory activity was displayed by two peptides containing cysteine in their sequence. Antibodies to two peptides containing the two conserved cysteine residues from opposite sides of the neutralizing loop of gp120 were previously associated with protection from vertical transmission of HIV. The V3 region thus seems to be important for the function of gp120 and the transmission of HIV.
Similar articles
-
Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.Antimicrob Agents Chemother. 1991 Oct;35(10):2003-11. doi: 10.1128/AAC.35.10.2003. Antimicrob Agents Chemother. 1991. PMID: 1722077 Free PMC article.
-
Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs.Antiviral Res. 1993 Dec;22(4):295-308. doi: 10.1016/0166-3542(93)90039-l. Antiviral Res. 1993. PMID: 7506513
-
Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.Antimicrob Agents Chemother. 1989 Dec;33(12):2083-8. doi: 10.1128/AAC.33.12.2083. Antimicrob Agents Chemother. 1989. PMID: 2533474 Free PMC article.
-
Mechanism of action of foscarnet against viral polymerases.Am J Med. 1992 Feb 14;92(2A):3S-7S. doi: 10.1016/0002-9343(92)90329-a. Am J Med. 1992. PMID: 1371038 Review.
-
Reverse transcriptase of HIV as a target for anti-viral drugs.Biochem Soc Trans. 1992 May;20(2):505-8. doi: 10.1042/bst0200505. Biochem Soc Trans. 1992. PMID: 1383062 Review. No abstract available.
Cited by
-
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007. Drugs. 1994. PMID: 7527325 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources